Yvonne Greenstreet Sells 8,301 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 8,301 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the transaction, the chief executive officer now owns 80,534 shares of the company’s stock, valued at approximately $18,602,548.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $247.00 on Friday. The stock has a market capitalization of $31.24 billion, a P/E ratio of -92.16 and a beta of 0.30. The company’s fifty day moving average is $157.89 and its two-hundred day moving average is $164.23. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. During the same period last year, the company earned ($1.40) earnings per share. The business’s revenue for the quarter was up 54.8% compared to the same quarter last year. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -3.75 EPS for the current year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Harbor Capital Advisors Inc. grew its stake in shares of Alnylam Pharmaceuticals by 1.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after purchasing an additional 51 shares during the period. EP Wealth Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 6.4% during the 3rd quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 71 shares during the period. Commerce Bank grew its stake in shares of Alnylam Pharmaceuticals by 1.7% during the 4th quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock worth $896,000 after purchasing an additional 77 shares during the period. Envestnet Portfolio Solutions Inc. grew its stake in shares of Alnylam Pharmaceuticals by 7.0% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 89 shares during the period. Finally, Metis Global Partners LLC grew its stake in shares of Alnylam Pharmaceuticals by 2.2% during the 4th quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company’s stock worth $839,000 after purchasing an additional 94 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday. Chardan Capital restated a “buy” rating and set a $225.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. BMO Capital Markets restated an “outperform” rating and set a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday. Citigroup boosted their price objective on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Wells Fargo & Company boosted their price objective on shares of Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Eight analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $245.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.